EGFR and non-small cell lung carcinoma: We feel that the combination of AA therapy, IO, and cytotoxic therapy may be beneficial for non-small-cell lung cancer (NSCLC) in the setting of metastatic disease without targetable mutations, brain metastases, locally advanced disease, and for recurrent EGFR-mutated (EGFRmut) disease.